Published in Lab Business Week, July 16th, 2006
Revenue for the third quarter of fiscal 2006 was $28.7 million, an increase of $2.0 million or 7.7% compared to the same quarter of the prior year.
Revenue for the 9 months ended April 30, 2006 was $82.6 million, also up $2.0 million over same period a year ago. Revenue for the quarter increased due to completion of delivery on the U.K.-government order for Vaccinia immune globulin ("VIG"), and stronger WinRho SDF sales in the U.S. following the transition in distributors from Nabi Biopharmaceuticals to Baxter Healthcare Corp. Sales of WinRho SDF in the U.S. improved...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.